Pembrolizumab induced remission of recurrent and metastatic sinonasal squamous cell carcinoma after overcoming checkpoint‐inhibitor pneumonitis: A case report and literature review

BACKGROUND: For programmed death‐ligand‐1 (PD‐L1) positive recurrent and metastatic head and neck squamous cell carcinoma (R/M‐HNSCC), KEYNOTE‐048 and KEYNOTE‐040 clinical trials recently approved pembrolizumab monotherapy as first‐line treatment. However, recurrent and metastatic sinonasal squamous...

Descripción completa

Detalles Bibliográficos
Autores principales: Nair, Deepak Rajendran, Trehan, Ram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363840/
https://www.ncbi.nlm.nih.gov/pubmed/36601913
http://dx.doi.org/10.1002/cnr2.1778

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363840/
https://www.ncbi.nlm.nih.gov/pubmed/36601913
http://dx.doi.org/10.1002/cnr2.1778

Ejemplares similares